Screener
Novavax
NVAXNovavax is a biotechnology company that develops and commercializes innovative vaccines to address serious infectious diseases.
Earnings
Next report
Nov 5, 2026 (in 2 months)Revenue estimate$72.7M
EPS estimate-$0.37
Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Novavax is a biotechnology company that develops and commercializes innovative vaccines to address serious infectious diseases. The company leverages a proprietary recombinant protein-based nanoparticle technology and its Matrix-M™ adjuvant to induce potent and durable immune responses. Its business strategy focuses on maximizing the value of its technology platform through strategic licensing and global partnerships.
Competitive position
A specialized vaccine developer known for its unique protein-based nanoparticle platform and potent Matrix-M adjuvant, often acting as a technology provider to larger pharmaceutical incumbents.
GeographiesUnited States, European Union, Australia, Global
Customer segmentsGovernments, Healthcare Providers, Pharmaceutical Companies
Business modelIP Licensing, Research and Development, Product Sales
SuppliersBaculovirus Sf-9 insect cell-expression systems, Raw material suppliers for adjuvant production, Contract manufacturing organizations (CMOs)
CustomersGovernment health agencies, Gavi, the Vaccine Alliance, Retail pharmacies, Hospitals and clinics
CountryUnited States of America
Listed1995
Employees2.0K
CEOJohn Charles Jacobs
SectorHealthcare
IndustryBiotechnology
Websitenovavax.com
FilingsSEC EDGAR
FAQ
- What is Novavax's market cap?
- Novavax (NVAX) has a market capitalization of $1.5B and trades on NASDAQ.
- What is Novavax's revenue and profitability?
- Novavax generated $413.8M in trailing twelve-month revenue with a net loss of $247.7M, representing a net margin of -59.9%. Gross margin stands at 78.6%, with free cash flow of -$276.6M. The latest reported period is Q2 2026.
- Who are Novavax's competitors?
- Novavax's key competitors include Moderna, Inc., Invivyd, Inc. Common Stock, GeoVax Labs, Inc. New, and others. These companies compete in similar markets and product categories.
- Who does Novavax partner with?
- Novavax's notable partners include Sanofi, Pfizer Inc., Serum Institute of India, and others.
- Where is Novavax headquartered?
- Novavax is headquartered in United States of America and employs approximately 1,992 people. It has been publicly traded since 1995.
